David C. Hornigold

This paper demonstrates that reversible peptide self-assembly can be used to achieve tuneable pharmacokinetics for therapeutic peptides, as shown with pramlintide in a rat model.

This study shows Prex1 regulates glucose homeostasis by reducing glucose uptake and mitochondrial metabolism in the liver, independent of its catalytic activity, through Gpr21 inhibition.

This paper shows P-Rex1 limits agonist-induced GPCR internalisation through its PDZ, DEP, and IP4P domains, independent of its Rac-GEF activity, by inhibiting phosphorylation and interacting with Grk2.

This study identifies a druggable PREX2/RAC1/PI3Kβ signalling axis in BRAF-mutant melanoma that confers resistance to therapies and can be targeted to improve treatment outcomes.